hbvaxpro
merck sharp & dohme b.v. - wzw typu b, rekombinowany antygen powierzchniowy - hepatitis b; immunization - szczepionki - 5 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis-b virus. poszczególnych grup ryzyka będą szczepione powinny być określone na podstawie oficjalnych zaleceń. można się spodziewać, że wirusowe zapalenie wątroby typu d jest również zapobiegać za pomocą szczepień z hbvaxpro jak wirusowe zapalenie wątroby typu d (nazwany agentem delta) nie występuje w przypadku braku wirusa zapalenia wątroby typu b zakażenia. 10 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals 16 years of age or more considered at risk of exposure to hepatitis-b virus. poszczególnych grup ryzyka będą szczepione powinny być określone na podstawie oficjalnych zaleceń. można się spodziewać, że wirusowe zapalenie wątroby typu d jest również zapobiegać za pomocą szczepień z hbvaxpro jak wirusowe zapalenie wątroby typu d (nazwany agentem delta) nie występuje w przypadku braku wirusa zapalenia wątroby typu b zakażenia. 40 micrograms hbvaxpro is indicated for the active immunisation against hepatitis-b-virus infection caused by all known subtypes in predialysis and dialysis adult patients. można się spodziewać, że wirusowe zapalenie wątroby typu d oraz będą zapobiegać poprzez szczepienia z hbvaxpro jak wirusowe zapalenie wątroby typu d (nazwany agentem delta) nie występuje w przypadku braku wirusa zapalenia wątroby typu b .
engerix b adult suspension for injection
glaxosmithkline biologicals s.a. - hepatitis b surface antigene (recombinant dna) - suspension for injection - 20mcg/ml
engerix b junior suspension for injection
glaxosmithkline biologicals s.a. - hepatitis b surface antigene (recombinant dna) - suspension for injection - 10mcg/0,5ml
hbvaxpro
merck sharp & dohme b.v. - hepatitis b, rekombinantni površinski antigen - hepatitis b; immunization - cjepiva - 5 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis-b virus. određene grupe rizika će biti cijepljeni moraju biti definirani na temelju službenih preporuka. može se očekivati da hepatitis d se također može spriječiti putem cijepljenja s hbvaxpro kao što su hepatitis d (uzrokovana agent delta) ne nalazi u nedostatku virusa hepatitis b infekcije. 10 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals 16 years of age or more considered at risk of exposure to hepatitis-b virus. određene grupe rizika će biti cijepljeni moraju biti definirani na temelju službenih preporuka. može se očekivati da hepatitis d se također može spriječiti putem cijepljenja s hbvaxpro kao što su hepatitis d (uzrokovana agent delta) ne nalazi u nedostatku virusa hepatitis b infekcije. 40 micrograms hbvaxpro is indicated for the active immunisation against hepatitis-b-virus infection caused by all known subtypes in predialysis and dialysis adult patients. može se očekivati da hepatitis d također će spriječiti stvaranje imunizacije s hbvaxpro kao što su hepatitis d (uzrokovana agent delta) ne nalazi u nedostatku virusa hepatitisa b .
hbvaxpro
merck sharp & dohme b.v. - hepatitis b, rekombinantes oberflächenantigen - hepatitis b; immunization - impfstoffe - 5 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis-b virus. die spezifische risiko-kategorien werden immunised werden ermittelt auf der grundlage der offiziellen empfehlungen. es kann davon ausgegangen werden, dass eine hepatitis d wird auch verhindert werden, dass durch die impfung mit hbvaxpro hepatitis d (verursacht durch das delta-agens) nicht auftreten, in der abwesenheit von hepatitis-b-infektion. 10 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals 16 years of age or more considered at risk of exposure to hepatitis-b virus. die spezifische risiko-kategorien werden immunised werden ermittelt auf der grundlage der offiziellen empfehlungen. es kann davon ausgegangen werden, dass eine hepatitis d wird auch verhindert werden, dass durch die impfung mit hbvaxpro hepatitis d (verursacht durch das delta-agens) nicht auftreten, in der abwesenheit von hepatitis-b-infektion. 40 micrograms hbvaxpro is indicated for the active immunisation against hepatitis-b-virus infection caused by all known subtypes in predialysis and dialysis adult patients. es kann davon ausgegangen werden, dass eine hepatitis d wird auch verhindert werden, dass durch die impfung mit hbvaxpro hepatitis d (verursacht durch das delta-agens) nicht auftreten, in der abwesenheit von hepatitis-b-infektion.
sci-b-vac 10 mcgml
scivac ltd, israel - hepatitis b vaccines - suspension for injection - hepatitis b vaccines 10 mcg/ml - hepatitis b, purified antigen - hepatitis b, purified antigen - for active immunization against hepatitis b virus. in high dose: it is indicated for imunization of neonates & children in highly endemic areas.
sci-b-vac 2.5 mcg0.5 ml
scivac ltd, israel - hepatitis b vaccines - suspension for injection - hepatitis b vaccines 2.5 mcg / 0.5 ml - hepatitis b, purified antigen - hepatitis b, purified antigen - for active immunization against hepatitis b virus. in high dose: it is indicated for immunization of neonates & children in highly endemic areas.
sci-b-vac 5 mcg0.5 ml
scivac ltd, israel - hepatitis b vaccines - suspension for injection - hepatitis b vaccines 5 mcg / 0.5 ml - hepatitis b, purified antigen - hepatitis b, purified antigen - for active immunization against hepatitis b virus. in high dose: it is indicated for immunization of neonates & children in highly endemic areas.
engerix-b vaccine 10 mcg0.5 ml
glaxosmithkline pte ltd - hepatitis b surface antigen protein (yeast) - injection - 10 mcg/0.5 ml - hepatitis b surface antigen protein (yeast) 10 mcg/0.5 ml
engerix™-b suspensie injectabila in seringa preumpluta 10 mcg/1 doza
glaxosmithkline biologicals s.a. - vaccin împotriva hepatitei virale b - suspensie injectabila in seringa preumpluta - 10 mcg/1 doza